Want to join the conversation?
$MNK's revenue from Specialty Brands for 1Q16 jumped by 45.4% to $543.2MM from last year, on strong commercial execution throughout the quarter, while that from Specialty Generics fell by 8.2% to $257.6MM, due to sales declines in oxycodone-related products and methylphenidate ER. Revenue from Nuclear Imaging increased by 6.1% TO $103.6MM.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.